Mitsuyama J, Itoh Y, Takahata M, Okamoto S, Yasuda T
Research Laboratory, Toyama Chemical Co., Ltd., Japan.
Antimicrob Agents Chemother. 1992 Sep;36(9):2030-6. doi: 10.1128/AAC.36.9.2030.
The antibacterial activities of tosufloxacin and other quinolones against and apparent uptakes of tosufloxacin and other quinolones by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium were studied. The hydrophobicity of tosufloxacin was nearly equal to that of ofloxacin or lower than those of sparfloxacin and nalidixic acid. OmpF- and OmpC-deficient E. coli and 40-kDa porin-deficient P. mirabilis mutants were twofold more susceptible to tosufloxacin and sparfloxacin but two- to fourfold less susceptible to other quinolones than their parent strains. In S. typhimurium lipopolysaccharide-deficient (rough) mutants, the differences in susceptibility to tosufloxacin were similar to those to sparfloxacin and nalidixic acid. The apparent uptake of tosufloxacin by intact cells was increased in porin-deficient mutants compared with that by their parent strain. These results suggest that the permeation route of tosufloxacin across the outer membrane is different from that of other fluoroquinolones and that tosufloxacin may permeate mainly through the nonporin pathway, presumably phospholipid bilayers. However, this characteristic is independent of the hydrophobicity of the molecule.
研究了妥舒沙星及其他喹诺酮类药物对大肠杆菌、奇异变形杆菌和鼠伤寒沙门氏菌外膜突变体的抗菌活性以及妥舒沙星和其他喹诺酮类药物的表观摄取情况。妥舒沙星的疏水性与氧氟沙星相近,或低于司帕沙星和萘啶酸。缺失OmpF和OmpC的大肠杆菌以及缺失40 kDa孔蛋白的奇异变形杆菌突变体对妥舒沙星和司帕沙星的敏感性是其亲本菌株的两倍,但对其他喹诺酮类药物的敏感性比对亲本菌株低两到四倍。在鼠伤寒沙门氏菌脂多糖缺陷(粗糙型)突变体中,对妥舒沙星的敏感性差异与对司帕沙星和萘啶酸的差异相似。与亲本菌株相比,孔蛋白缺陷突变体中完整细胞对妥舒沙星的表观摄取增加。这些结果表明,妥舒沙星跨外膜的渗透途径与其他氟喹诺酮类药物不同,妥舒沙星可能主要通过非孔蛋白途径渗透,推测是通过磷脂双层。然而,这一特性与分子的疏水性无关。